APOGEE THERAPEUTICS INC

Insight: Apogee Therapeutics’ insider trades reveal disciplined buying at discount levels and profit‑taking on highs, hinting at management confidence and potential merger upside.

Insider sales by Apogee Therapeutics’ CMO and CEO after AbbVie’s $135‑per‑share acquisition bid show planned exits, not panic, and hint at investor confidence in the deal.

Apogee Therapeutics CEO sells $1.2 M in shares, but keeps 18% stake; insider trades show disciplined strategy, not a bearish signal for investors.

APOGEE insider buys reveal cautious optimism: CMO Carl Dambkowski’s $22.86 purchases, paired with a 10b5‑1 plan, suggest confidence amid a $6.35 B cap and pipeline‑driven upside.

Insider selling continues at Apogee Therapeutics – CFO Jane Henderson’s recent $180 k sale shows routine divestment amid a 32 % monthly rally, not a warning. Stay alert to future clinical milestones for better investment decisions.

Apogee Therapeutics CFO Jane Henderson sells 2,000 shares at $85.00—an insider move reflecting confidence amid a $350 million offer and rising stock.

Insider buy‑the‑dip by Apogee’s CMO Carl Dambkowski: 4,125 shares at $73.08 hints at near‑term upside despite negative earnings, fueling a balanced investor outlook.

Insider CFO sells 2,700 Apogee shares at $70.45/stock, showing disciplined Rule 10b5‑1 trades, not panic—investors can gauge future pipeline upside.